Ganaxolone

Marinus Pharmaceuticals to Present at Upcoming Investor Conferences

Retrieved on: 
星期三, 九月 7, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, Patient, CDKL5, CV, IV, Seizure, Brain, Medication, GABAA, Conference, Therapy, Adult, Investor, Ganaxolone, Epilepsy, Pharmaceutical industry

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present and participate in the following investor conferences in September.

Key Points: 
  • Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present and participate in the following investor conferences in September.
  • H.C. Wainwright 24th Annual Global Investment Conference (New York, NY) on Wednesday, September 14 at 12:00 p.m.
  • Links to each event can be accessed on the Investors & Media page of Marinus website at ir.marinuspharma.com/events-and-presentations .
  • Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders.

Marinus Pharmaceuticals Announces Closing of Sale of Priority Review Voucher for $110 Million

Retrieved on: 
星期一, 八月 29, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Patient, COVID-19, EMA, Security (finance), Program, CDKL5, CV, IV, Seizure, Brain, Medication, Sale, Jefferies Group, GABAA, China Biologic Products, New Drug Application, Ganaxolone, Food, U.S. Securities and Exchange Commission, PRV, Company, FDA, Therapy, LLC, Adult, Clinical trial, Private Securities Litigation Reform Act, Review, Forward-looking statement, Epilepsy, Pharmaceutical industry

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has closed on the sale of its Rare Pediatric Disease Priority Review Voucher for $110 million.

Key Points: 
  • Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has closed on the sale of its Rare Pediatric Disease Priority Review Voucher for $110 million.
  • The $110 million of gross funds have been received and are in addition to the $92.3 million in cash and cash equivalents reported as of June 30, 2022.
  • Jefferies LLC acted as the exclusive financial advisor to Marinus for this transaction.
  • The sponsor may choose to sell or transfer the voucher upon approval of the rare pediatric disease product application.

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Retrieved on: 
星期五, 八月 12, 2022
Professional Services, Health, Finance, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Cyprus Securities and Exchange Commission, Forward-looking statement, Epilepsy, IV, GABAA, Private Securities Litigation Reform Act, Brain, Board, Security (finance), CDKL5, CV, Financial compensation, Common stock, Patient, Company, Therapy, Ganaxolone, Seizure, Medication, Employment, Adult, Pharmaceutical industry

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to seven new employees.

Key Points: 
  • (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to seven new employees.
  • The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 57,975 shares of its common stock (the Common Stock) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The stock options were granted as an inducement material to each of the employees entering into employment with Marinus in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the applicable award agreement covering such grant.
  • Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders.

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Retrieved on: 
星期五, 七月 15, 2022
Professional Services, Health, Finance, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Adult, Patient, Security (finance), Employment, Seizure, Cyprus Securities and Exchange Commission, CV, CDKL5, GABAA, Therapy, Private Securities Litigation Reform Act, Financial compensation, Forward-looking statement, Brain, Medication, Common stock, Board, Company, Ganaxolone, Epilepsy, IV, Pharmaceutical industry

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to 13 new employees.

Key Points: 
  • (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to 13 new employees.
  • These restricted stock units vest in full on the first anniversary of the applicable employees start date of employment.
  • The stock options and restricted stock units were granted as an inducement material to each of the employees entering into employment with Marinus in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the applicable award agreement covering such grant.
  • Marinus is a commercial stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders.

Marinus Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher for $110 Million

Retrieved on: 
星期四, 七月 14, 2022
Research, FDA, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, New Drug Application, Clinical trial, Security (finance), Sale, Jefferies Group, IV, U.S. Securities and Exchange Commission, Seizure, LLC, Program, GABAA, Ganaxolone, Company, Risk, EMA, Patient, Epilepsy, CDKL5, Review, PRV, Adult, Food, Brain, COVID-19, China Biologic Products, Private Securities Litigation Reform Act, Therapy, Forward-looking statement, CV, FDA, Food and Drug Administration, Status epilepticus, Medication, Pharmaceutical industry

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $110 million.

Key Points: 
  • Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $110 million.
  • Marinus received the voucher in March 2022 under a U.S. Food and Drug Administration program intended to encourage the development of treatments for rare pediatric diseases.
  • The U.S. Food and Drug Administration Rare Pediatric Disease Priority Review Program is intended to encourage the development of new drug and biological products for the prevention and treatment of certain rare pediatric diseases.
  • The sponsor may choose to sell or transfer the voucher upon approval of the rare pediatric disease product application.

Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2022 Financial Results on August 11, 2022

Retrieved on: 
星期三, 七月 13, 2022
Pharmaceutical, Health, Other Health, IV, Seizure, GABAA, Ganaxolone, Company, Patient, Epilepsy, CDKL5, Adult, Brain, Webcast, Therapy, CV, Medication, Pharmaceutical industry

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2022 before the U.S. financial market opens on August 11, 2022.

Key Points: 
  • Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2022 before the U.S. financial market opens on August 11, 2022.
  • The Company will host a conference call at 8:30 a.m. Eastern Time on August 11, 2022.
  • Participants may access the conference call via webcast on the Investor page of Marinus website at ir.marinuspharma.com/events-and-presentations .
  • Marinus is a commercial stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders.

Marinus Pharmaceuticals Expands Enrollment Criteria to Support Recruitment in Phase 3 RAISE Trial in Refractory Status Epilepticus

Retrieved on: 
星期三, 六月 8, 2022
Pharmaceutical, Health, Clinical Trials, Benzodiazepine, Adult, Seizure, Company, IV, EMA, CDKL5, Food, Status epilepticus, Biomedical Advanced Research and Development Authority, Forward-looking statement, Security (finance), Office of Inspector General, U.S. Department of Health and Human Services, U.S. Securities and Exchange Commission, Medication, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Therapy, Brain, Coronavirus Scientific Advisory Board (Turkey), FDA, Development, Patient, Assistant, Hospital, Private Securities Litigation Reform Act, GABAA, Human services, BARDA, COVID-19, Adoption, SE, Epilepsy, Clinical trial, Population, RSE, CV, RAISE, Ganaxolone, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Office of the Assistant Secretary for Preparedness and Response, Safety, Pharmaceutical industry

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has amended the protocol for its Phase 3 RAISE trial in refractory status epilepticus (RSE) to expand eligibility criteria, support patient recruitment and drive enrollment efficiencies at clinical sites.

Key Points: 
  • Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has amended the protocol for its Phase 3 RAISE trial in refractory status epilepticus (RSE) to expand eligibility criteria, support patient recruitment and drive enrollment efficiencies at clinical sites.
  • Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia, as well as patients transferred from other hospitals or treated in the emergency room.
  • Marinus expects that the vast majority of sites will adopt these protocol updates by the middle of the third quarter of 2022.
  • Marinus reached alignment with the U.S. Food and Drug Administration on the protocol amendment, including a proposal for a potential interim analysis.

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Retrieved on: 
星期五, 六月 3, 2022
General Health, Pharmaceutical, Health, Financial compensation, Adult, Company, Common stock, Forward-looking statement, Security (finance), Cyprus Securities and Exchange Commission, Medication, Therapy, Brain, Private Securities Litigation Reform Act, Employment, GABAA, Epilepsy, Board, Ganaxolone, Pharmaceutical industry

(Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to 11 new employees.

Key Points: 
  • (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to 11 new employees.
  • The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 116,625 shares of its common stock (the Common Stock) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The stock options were granted as an inducement material to each of the employees entering into employment with Marinus in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the applicable award agreement covering such grant.
  • Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.

Marinus Pharmaceuticals to Present at Upcoming Medical and Investor Conferences

Retrieved on: 
星期三, 五月 18, 2022
Biotechnology, General Health, Pharmaceutical, Health, GABAA, Brain, Therapy, Ganaxolone, IV, Epilepsy, Adult, Risk management, Pharmaceutical industry

May 22 25 in Madrid, Spain

Key Points: 
  • May 22 25 in Madrid, Spain
    This event is closed to conference participants only.
  • This presentation will be closed to conference participants only.
  • Marinus is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.
  • Ganaxolone is a neuroactive steroid GABAA receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects.

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Retrieved on: 
星期二, 五月 10, 2022
Professional Services, Health, Human Resources, Research, Science, Pharmaceutical, Biotechnology, Board, Cyprus Securities and Exchange Commission, Forward-looking statement, Common stock, Private Securities Litigation Reform Act, Brain, Employment, Epilepsy, Company, Security (finance), Therapy, Adult, GABAA, Medication, Ganaxolone, Financial compensation, Pharmaceutical industry

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to 15 new employees.

Key Points: 
  • (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to 15 new employees.
  • The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 122,300 shares of its common stock (the Common Stock) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The stock options were granted as an inducement material to each of the employees entering into employment with Marinus in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the applicable award agreement covering such grant.
  • Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.